Table 4

Data taken from clinical and electronic records of those recruited to the MaCROS study

Patient no	Age	Probiotic/ placebo	Diagnosis	Inpatient (routine chemotherapy)	Was routine admission for chemotherapy extended?	Febrile	Febrile neutropenic?	Positive blood culture?	Organism
1*	12 years	Probiotic	Ewing’s sarcoma	Yes	No	No	No	N/A
2	13 years	Placebo	Osteosarcoma	Yes	Yes	Yes	No	No
3	7 years	Probiotic	Undifferentiated sarcoma	Yes	No	No	No	NA
4	12 years	Placebo	HR NBL- HD chemo and stem cell rescue	Yes	NA†	Yes	Yes	No
5	1 year, 7 months	Probiotic	HR NBL	Yes	No	No	No	Yes	Streptococcus mitis/oralis, Streptococcus vestibularis, Streptococcus parasangui
6	1 year, 7 months	Probiotic	HR NBL HD chemo and stem cell rescue	Yes	NA†	Yes	No	Yes	Gram negative bacilli
7	14 years	Placebo	AML	Yes	NA†	Yes	Yes	No
8	3 years	Placebo	NHL	Yes	Yes	Yes	Yes	No
9*	15 years	Placebo	Metastatic-relapsed osteosarcoma	No	No	No	No	NA
10	8 years	Placebo	Osteosarcoma	Yes	Yes	Yes	No	No

*Withdrawn.
†Inpatient until count recovered.
AML, acute myeloid leukaemia; HD, high dose; HR NBL, high-risk neuroblastoma; NHL, non-Hodgkins lymphoma.